


**Amendments to the Claims**

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A compound of formula I:



FORMULA I

or a pharmaceutically acceptable salt, enantiomer, diastereomer or in vivo hydrolysable ester or mixture thereof, ~~wherein,~~ wherein:

~~R<sup>1</sup> represents~~ is selected from the group consisting of C<sub>6-10</sub> aryl, C<sub>5-10</sub> heteroaryl or C<sub>5-10</sub> heterocyclic groups, said aryl, heteroaryl and ~~heterocyclic~~ heterocyclic groups optionally substituted with 1 to 3 groups of R<sup>a</sup>.

~~R<sup>a</sup> represents~~ is selected from the group consisting of C<sub>1-6</sub> alkyl, halogen, ~~OH~~ hydroxy, aryl(C<sub>1-6</sub>)alkyl, (C<sub>1-6</sub>)alkoxy, (C<sub>1-6</sub>)alkoxy(C<sub>1-6</sub>)alkyl, halo(C<sub>1-6</sub>)alkyl, nitro, amino, mono- or di-N-(C<sub>1-6</sub>)alkylamino, acylamino, acyloxy, carboxy, carboxy salts, carboxy esters, carbamoyl, mono- and di-N-(C<sub>1-6</sub>)alkylcarbamoyl, (C<sub>1-6</sub>)alkoxycarbonyl, aryloxy carbonyl, ureido, guanidine, sulphonylamino, aminosulphonyl, (C<sub>1-6</sub>)alkylthio, (C<sub>1-6</sub>)alkylsulphanyl, (C<sub>1-6</sub>)alkylsulphonyl, heterocyclyl, and heterocyclyl(C<sub>1-6</sub>)alkyl groups; and

~~R represents~~ is selected from the group consisting of C<sub>1-8</sub> alkyl, C<sub>3-10</sub> cycloalkyl, C<sub>3-10</sub> heterocycloalkyl, C<sub>5-10</sub> heteroaryl, ~~or and~~ C<sub>5-11</sub> heterocyclic groups, said heteroaryl and ~~heterocyclic~~ heterocyclic groups are optionally substituted with 1 to 3 groups of R<sup>a</sup> and said alkyl, ~~optionally~~ C<sub>1-8</sub> alkyl groups are substituted with ~~1-3~~ 1 to 3 groups selected from the group consisting of aryl, heterocyclyl, (C<sub>1-6</sub>)alkylthio, cyano, heteroaryl, guanidino, ((1-aminoethyl)carbonyl)amino, ((aminomethyl)carbonyl)amino,

RECEIVED  
CENTRAL FAX CENTER

MAY 09 2007

Serial No. 10/509,972

Case No. 21111YP

((2-amino)prop-2-yl) carbonyl)amino, acetamido, 4-(aminomethyl)phenyl, thio, t-butyl sulfonyl, (C<sub>2-6</sub>)alkenylthio, (C<sub>2-6</sub>)alkynylthio, amino, mono- or di-(C<sub>1-6</sub>)alkylamino, arylthio, heterocyclylthio, (C<sub>1-6</sub>)alkoxy, aryl(C<sub>1-6</sub>)alkoxy, aryl(C<sub>1-6</sub>)alkylthio, cycloalkyl, cycloalkenyl, carboxy and esters thereof, hydroxy and halogen groups.

2. (Currently Amended) ~~A-The compound according to claim 1~~  
~~wherein claim 1, wherein R is a heterocycloalkyl and all other variables are as originally~~  
~~described.~~

3. (Currently Amended) ~~A-The compound according to claim 1~~  
~~wherein claim 1, wherein R is a heteroaryl and all other variables are as originally~~  
~~described.~~


4. (Currently Amended) ~~A-The compound according to claim 1~~  
~~wherein claim 1, wherein R<sup>1</sup> is a phenyl group optionally substituted with 1-3-1 to 3~~  
~~groups of R<sup>a</sup> and R is a heterocycloalkyl, or heteroaryl heterocycloalkyl or heteroaryl~~  
~~group.~~

5. (Currently Amended) ~~A-The compound according to claim 1~~  
~~wherein claim 1, R<sup>1</sup> is a phenyl group substituted with 1 to 3 groups of methoxy, halogen,~~  
~~methyl, ethyl, propyl, butyl, naphthyl, 5-(2-pyridyl)thiophen-2-yl or a mixture thereof, and~~  
~~R is a heterocycloalkyl or heteroaryl group.~~























6. (Currently Amended) ~~A-The compound according to claim 1~~  
~~which claim 1, wherein the compound is selected from the group consisting of:~~  
~~N-t-butoxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-methylbutyramide;~~  
~~N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-methylbutyramide;~~  
~~N-t-butoxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-~~  
~~acetamide;~~  
~~N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-~~  
~~acetamide;~~  
~~N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-(S)-~~

cyclopropylbutyramide; and from  
compounds provided in tables 1 and 2 below

Table 1























Example #	R1R1	R2R2
3		
4		
5		
6		
7		
8		
9		

10		
11		
<del>12</del>		
13		
14		
15		
16		
17		
<del>18</del>		
19		
20		





















Serial No. 10/509,972

Case No. 21111YP

21		
22		
23		
24		
25		
26		
27		
28		
29		
30		





















Serial No. 10/509,972

Case No. 21111YP

31		
32		
33		
34		
35		
36		
37		
38		
39		
40		























Serial No. 10/509,972

Case No. 21111YP

41		
42		
43		
44		
45		
46		
47		
48		
49		
50		

Serial No. 10/509,972





















Case No. 21111YP





















51		
52		
53		
54		
55		
56		
57		
58		
59		
60		
61		



Serial No. 10/509,972























Case No. 21111YP

62		
63		
64		
65		
66		
67		
68		
69		
70		
71		

72		
73		
74		
75		
76		
77		
78		
79		
80		
81		





















Serial No. 10/509,972

Case No. 21111YP

82		
83		
84		
85		
86		
87		
88		
89		
90		
91		
92		





















Serial No. 10/509,972

Case No. 21111YP

93		
94		
95		
96		
97		
98		
99		
100		
101		
102		

























Serial No. 10/509,972

Case No. 21111YP



























103		
104		
105		
106		
107		
108		
109		
110		
111		
112		

Serial No. 10/509,972

Case No. 21111YP

113		
114		
115		
116		
117		
118		
119		
120		
121		
122		
123		
124		

Serial No. 10/509,972  
Case No. 21111YP

125		
126		
127		
128		
129		
130		
131		
132		
133		
134		
135		
136		
137		

Serial No. 10/509,972

Case No. 21111YP

















138		
139		
140		
141		
142		
143		
144		

Table 2










Example #	R <sub>1</sub> R <sub>1</sub>	R <sub>2</sub> R <sub>2</sub>
146		Me



Serial No. 10/509,972

Case No. 21111YP

147		Me
148		Me
149		H
150		Me
151		Me
152		Me
153		Me

and pharmaceutically acceptable salts, enantiomers, ~~diastereomers or in~~ diastereomers, in vivo hydrolysable esters ~~or and~~ mixtures thereof.

7. (Currently Amended) ~~A-The compound according to claim 6~~  
~~which claim 6, wherein the compound is selected from the group consisting of:~~  
~~N-t-butoxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-methylbutyramide;~~  
~~N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-methylbutyramide;~~  
~~N-t-butoxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-~~  
~~acetamide;~~  
~~N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-~~  
~~acetamide;~~  
~~N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-(S)-~~  
~~cyclopropylbutyramide; and pharmaceutically acceptable salts, enantiomers,~~  
~~diastereomers or in~~ diastereomers, in vivo hydrolysable esters ~~or and~~ mixtures thereof.

8. (Currently Amended) ~~A-The compound according to claim 7 which~~  
~~is claim 7, wherein the compound is selected from the group consisting of:~~  
~~N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-methylbutyramide; or~~

N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-acetamide; and pharmaceutically acceptable salts, enantiomers, ~~diastereomers or in diastereomers, in vivo hydrolysable esters or and mixtures thereof.~~

9. (Currently Amended) A composition ~~according to claim 1,~~ comprising a compound of ~~formula I according to claim 1~~ and a pharmaceutically acceptable carrier.

10. (Currently Amended) A method of inhibiting the activity of lethal factor (LF) released from bacterial in a ~~mammal comprising administration mammal, the method comprising:~~

administering to a patient in need thereof a therapeutically effective amount of a compound of structural formula I



FORMULA I

or a pharmaceutically acceptable salt, enantiomer, diastereomer or in vivo hydrolysable ester or mixture thereof, wherein,

~~R<sup>1</sup> represents~~ is selected from the group consisting of C<sub>6-10</sub> aryl, C<sub>5-10</sub> heteroaryl ~~or and~~ C<sub>5-10</sub> heterocyclic groups, said aryl, heteroaryl and heterocyclic groups ~~heterocyclicly~~ optionally substituted with 1 to 3 groups of R<sup>a</sup>R<sup>a</sup>,

~~R<sup>a</sup> represents~~ is selected from the group consisting of C<sub>1-6</sub>alkyl, halogen, OH, aryl(C<sub>1-6</sub>)alkyl, (C<sub>1-6</sub>)alkoxy, (C<sub>1-6</sub>)alkoxy(C<sub>1-6</sub>)alkyl, halo(C<sub>1-6</sub>)alkyl, nitro, amino, mono- or di-N-(C<sub>1-6</sub>)alkylamino, acylamino, acyloxy, carboxy, carboxy salts, carboxy esters, carbamoyl, mono- and di-N-(C<sub>1-6</sub>)alkylcarbamoyl, (C<sub>1-6</sub>)alkoxycarbonyl, aryloxy carbonyl, ureido, guanidine, sulphonylamino, aminosulphonyl, (C<sub>1-6</sub>)alkylthio, (C<sub>1-6</sub>)alkylsulphanyl, (C<sub>1-6</sub>)alkylsulphonyl, heterocyclyl, and heterocyclyl(C<sub>1-6</sub>)alkyl groups; and


Serial No. 10/509,972

Case No. 21111YP

R represents ~~is selected from the group consisting of~~ C<sub>1-8</sub> alkyl, C<sub>3-10</sub> cycloalkyl, C<sub>3-10</sub> heterocycloalkyl, C<sub>3-10</sub> heteroaryl, or C<sub>5-11</sub> heterocyclyl, said heteroaryl and heterocyclyl groups are optionally substituted with 1 to 3 groups of R<sup>a</sup> ~~and R<sup>a</sup>~~, and said ~~alkyl~~, optionally C<sub>1-8</sub> alkyl groups are substituted with ~~1-3~~ 1 to 3 groups selected from the group consisting of aryl, heterocyclyl, (C<sub>1-6</sub>)alkylthio, cyano, heteroaryl, guanidino, ((1-aminoethyl)carbonyl)amino, ((aminomethyl)carbonyl)amino, ((2-amino)prop-2-yl)carbonyl)amino, acetamido, 4-(aminomethyl)phenyl, thio, t-butyl sulfonyl, (C<sub>2-6</sub>)alkenylthio, (C<sub>2-6</sub>)alkynylthio, amino, mono- or di-(C<sub>1-6</sub>)alkylamino, arylthio, heterocyclylthio, (C<sub>1-6</sub>)alkoxy, aryl(C<sub>1-6</sub>)alkoxy, aryl(C<sub>1-6</sub>)alkylthio, cycloalkyl, cycloalkenyl, carboxy and esters thereof, hydroxy and halogen groups.

11. (Currently Amended) A ~~The~~ method according to ~~claim 11~~ ~~wherein claim 10, wherein~~ the compound is selected from the group consisting of:  
~~N-t-butoxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-methylbutyramide;~~  
~~N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-methylbutyramide;~~  
 N-t-butoxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-acetamide;  
 N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-acetamide;  
 N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-(S)-cyclopropylbutyramide; and ~~from~~  
 compounds provided in tables 1 and 2 below





















Table 1

























Example #	R1R1	R2R2
3		

Serial No. 10/509,972























Case No. 21111YP

4		
5		
6		
7		
8		
9		
10		
11		
<del>12</del>		
13		

14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		





















Serial No. 10/509,972

Case No. 21111YP

25		
26		
27		
28		
29		
30		
31		
32		
33		
34		
35		























Serial No. 10/509,972

Case No. 21111YP

36		
37		
38		
39		
40		
41		
42		
43		
44		
45		





















Serial No. 10/509,972

Case No. 21111YP

46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		























Serial No. 10/509,972  
Case No. 21111YP























57		
58		
59		
60		
61		
62		
63		
64		
65		
66		























Serial No. 10/509,972

Case No. 21111YP

67		
68		
69		
70		
71		
72		
73		
74		
75		
76		





















Serial No. 10/509,972  
Case No. 21111YP

77		
78		
79		
80		
81		
82		
83		
84		
85		
86		
87		

88		
89		
90		
91		
92		
93		
94		
95		
96		
97		
98		























Serial No. 10/509,972

Case No. 21111YP

























99		
100		
101		
102		
103		
104		
105		
106		
107		
108		

Serial No. 10/509,972

Case No. 21111YP

























109		
110		
111		
<del>112</del>		
113		
<del>114</del>		
<del>115</del>		
<del>116</del>		
117		
<del>118</del>		
119		

Serial No. 10/509,972  
Case No. 21111YP

120		
<del>121</del>		
122		
<del>123</del>		
<del>124</del>		
125		
126		
127		
<del>128</del>		
<del>129</del>		
130		
<del>131</del>		

Serial No. 10/509,972

Case No. 21111YP

132		
133		
134		
135		
136		
137		
138		
139		
140		
141		
142		
143		



Serial No. 10/509,972

Case No. 21111YP













Table 2



Example #	R1R1	R2R2
146		Me
147		Me
148		Me
149		H
150		Me
151		Me
152		Me
153		Me

and pharmaceutically acceptable salts, enantiomers, ~~diastereomers or in~~ diastereomers, in vivo hydrolysable esters or and mixtures thereof.

Serial No. 10/509,972

Case No. 21111YP

12. (Currently Amended) ~~A~~ The method according to claim 11 ~~wherein claim 11, wherein~~ the compound is selected from the group consisting of:  
N-t-butoxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-methylbutyramide;  
N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-methylbutyramide;  
N-t-butoxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-acetamide;  
N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-acetamide;  
N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-(S)-cyclopropylbutyramide; and pharmaceutically acceptable salts, enantiomers, ~~diastereomers or in diastereomers,~~ in vivo hydrolysable esters ~~or and~~ mixtures thereof.
13. (Currently Amended) ~~A~~ The method according to claim 12 wherein claim 12, wherein the compound is selected from the group consisting of:  
N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-3-methylbutyramide; or  
N-hydroxy-2(R)-[(4-fluoro-3-methylphenylsulfonyl)]amino-2-(4'-tetrahydropyranyl)-acetamide; and pharmaceutically acceptable salts, enantiomers, ~~diastereomers or in diastereomers,~~ in vivo hydrolysable esters ~~or and~~ mixtures thereof.
14. (Currently Amended) ~~A~~ The method according to claim 10 ~~wherein claim 10, wherein~~ said administering further comprises administering the compound of formula I ~~is combined in combination~~ with one or more known drugs selected from beta-lactams, aminoglycosides, inhibitors of beta-lactamase, renal tubular blocking agents and inhibitors or metabolizing enzymes, N-acylated amino acids.
15. (Currently Amended) ~~A~~ The method according to claim 14 ~~wherein claim 14, wherein~~ the known drugs are selected from the group consisting of imipenem, meropenem, vancomycin, cilastatin, cefoxitin, penicillin, clavulanic acid, probenecid, tetracycline, ciprofloxacin, and norfloxacin or a mixture thereof, wherein when imipenem is used as a drug it is used in combination with cilastatin as PRIMAXIN®.